3402
S.-W. Chen et al. / Tetrahedron 65 (2009) 3397–3403
J¼15.8, 6.6 Hz, 1H), 4.55–4.50 (m, 1H), 3.60–3.42 (m, 2H), 1.90 (dd,
J¼6.6, 1.8 Hz, 3H), 1.28 (d, J¼6.2 Hz, 3H) ppm; 13C NMR (62.5 MHz,
4.2.13. Imidazolium ion-tagged Ru-carbene complexes 7a,b
and 8a,b
CDCl3)
d
153.8, 128.7, 127.7, 126.6, 125.5, 121.8, 121.2, 114.8, 74.4,
A degassed solution of 13a (14.9 mg, 0.031 mmol), Grubbs 2nd-
35.6, 18.9, 14.7 ppm. IR: 3041, 2976, 2398, 2071, 1602, 1453, 1278,
1230, 1140, 1026, 950, 742 cmꢂ1
generation
catalyst,
RuCl2(]CHPh)(PCy3)(NHC),
(40.0 mg,
.
0.047 mmol), and CuCl (3.88 mg, 0.039 mmol) in dry dichloro-
methane (5 mL) was stirred at room temperature for 1 h. After
short column silica chromatography (MC/MeOH¼9/1, v/v), the
resulting material was treated with a mixture of CH2Cl2/pentane
(1/1, v/v) to provide the pure imidazolium-tagged Ru-carbene
complexes 7a as air-stable, greenish powder (56.6 mg, 72%). 1H
4.2.9. 3-Methyl-1-[2-(2-propenylphenoxy)]propyl-3H-imidazolium
bromide (15a)
A 100 mL round bottomed flask equipped with a condenser was
charged with compound 14 (2.5 g, 9.80 mmol), 1-methyl-1H-im-
idazole (1.61 g, 19.60 mmol), and anhydrous acetonitrile (50 mL).
The mixture was refluxed for 36 h and cooled to room temperature.
After evaporation of the solvent, the residue was washed with
diethyl ether (3ꢁ30 mL) to afford imidazolium bromide 15a as
slightly yellow oil (3.17 g, 95.6%). The spectral data of major isomer:
NMR (250 MHz, CDCl3)
d 16.62 (s, 1H), 8.30 (s, 1H), 7.51–7.47 (m,
1H), 7.08–6.97 (m, 8H), 6.84–6.83 (m, 2H), 4.98–4.96 (m, 1H), 4.15
(s, 4H), 4.10–3.84 (m, 2H), 3.68–3.60 (m, 2H), 3.55 (s, 3H), 3.32–
3.26 (m, 2H), 3.15–3.12 (m, 1H), 2.43–2.29 (m, 18H), 1.74–1.70 (m,
2H), 1.45–1.42 (m, 2H), 1.20 (d, J¼6.3 Hz, 3H) ppm; 13C NMR
1H NMR (250 MHz, CD2Cl2)
d
9.95 (s, 1H), 7.62 (d, J¼1.4 Hz, 1H), 7.50
(62.5 MHz, CDCl3) d 296.4, 209.8, 152.3, 144.6, 139.0, 130.1, 129.8,
(d, J¼1.5 Hz,1H), 7.37 (dd, J¼7.6,1.4 Hz,1H), 7.14–7.07 (m, 1H), 6.92–
6.83 (m, 2H), 6.64 (dq, J¼15.9, 1.5 Hz, 1H), 6.20 (dq, J¼15.9, 6.6 Hz,
1H), 4.89–4.84 (m, 2H), 4.56–4.41 (m, 1H), 3.98 (s, 3H), 1.90 (dd,
J¼6.6, 1.5 Hz, 3H), 1.33 (d, J¼6.1 Hz, 3H) ppm; 13C NMR (62.5 MHz,
129.4, 123.6, 123.4, 123.1, 122.8, 122.3, 122.2, 113.5, 73.6, 70.2, 51.6,
49.4, 36.0, 27.6, 25.1, 21.1, 18.8, 17.4, 17.1 ppm; HRMS (m/z) Calcd
for [M]þ: C39H51Cl2F6N4O2PRuþ: 924.2069. Found: 924.2074.
Compound 7b was prepared from 13b. Yield: 78%. 1H NMR
CD2Cl2)
d
151.2, 135.9, 128.6, 126.4, 126.0, 125.1, 124.6, 123.3, 121.4,
(250 MHz, CDCl3) d 16.57 (s, 1H), 7.56–7.52 (m, 2H), 7.10–7.04 (m,
121.3, 119.9, 112.4, 71.3, 34.7, 16.9, 14.8 ppm. IR: 3374, 3049, 2956,
2434, 2090, 1594, 1453, 1238, 970, 888, 761, 618, 536 cmꢂ1
5H), 6.96 (d, J¼8.2 Hz, 1H), 6.84–6.82 (m, 2H), 4.99–4.93 (m, 1H),
4.14 (s, 4H), 3.70–3.62 (m, 5H), 3.30–3.25 (m, 4H), 2.44–2.30 (m,
18H), 1.63–1.58 (m, 2H), 1.47–1.44 (m, 2H), 1.19 (d, J¼6.3 Hz, 3H)
.
4.2.10. 2,3-Methyl-1-[2-(2-propenylphenoxy)]propyl-3H-
imidazolium bromide (15b)
ppm; 13C NMR (62.5 MHz, CDCl3)
d 296.6, 210.1, 152.4, 144.6, 143.5,
139.0, 129.8, 128.7, 127.5, 126.4, 123.6, 122.6, 122.1, 120.7, 113.5,
73.5, 70.0, 51.5, 48.1, 34.9, 26.8, 25.8, 21.1, 19.3, 17.4, 16.9, 9.1 ppm;
HRMS (m/z) Calcd for [M]þ: C40H53Cl2F6N4O2PRuþ: 938.2225.
Found: 938.2231. Compound 8a was prepared from 16a. Yield:
Prepared by the same method for 15a using 1,2-dimethylimi-
dazole. Yield: 94%. The spectral data of major isomer: 1H NMR
(250 MHz, CD2Cl2)
d
7.88 (d, J¼2.1 Hz, 1H), 7.58 (d, J¼2.1 Hz, 1H),
7.28 (dd, J¼7.6, 1.5 Hz, 1H), 7.04–6.98 (m, 1H), 6.82–6.70 (m, 2H),
6.48 (dq, J¼15.9, 1.5 Hz, 1H), 6.09 (dq, J¼15.9, 6.6 Hz, 1H), 4.84–4.70
(m, 2H), 4.40–4.34 (m, 1H), 3.78 (s, 3H), 2.67 (s, 3H), 1.79 (dd, J¼7.0,
1.8 Hz, 3H), 1.30 (d, J¼6.1 Hz, 3H) ppm; 13C NMR (62.5 MHz, CD2Cl2)
77%; 1H NMR (250 MHz, CDCl3)
d 16.64 (s, 1H), 8.25 (s, 1H), 7.53–
7.26 (m, 4H), 6.96–6.84 (m, 5H), 6.50–6.48 (m, 1H), 5.37–5.34 (m,
1H), 4.45–4.18 (m, 4H), 3.53 (s, 3H), 2.47–2.31 (m, 18H), 1.26 (d,
J¼6.3 Hz, 3H) ppm; 13C NMR (62.5 MHz, CDCl3)
d 297.4, 208.9,
d
151.1, 142.9, 128.5, 126.3, 126.0, 124.9, 124.5, 123.3, 120.8, 120.3,
151.8, 143.7, 140.9, 139.2, 134.9, 130.1, 129.5, 129.0, 126.5, 124.1,
123.5, 122.6, 111.2, 53.8, 51.6, 36.5, 21.1, 19.4, 17.8, 17.5 ppm. IR:
3058, 2990, 2308, 1430, 1267, 897, 843, 742, 561 cmꢂ1; HRMS
(m/z) Calcd for [MꢂHPF6]þ: C35H43Cl2N4ORuþ: 707.1861. Found:
707.1892. Compound 8b was prepared from 16b. Yield: 78%; 1H
119.8, 112.3, 71.6, 33.9, 16.8, 14.9, 9.1 ppm. IR: 3366, 3067, 2957,
1594, 1492, 1456, 1266, 1241, 1131, 1041, 976, 894, 742 cmꢂ1
.
4.2.11. 3-Methyl-1-[2-(2-propenylphenoxy)]propyl-3H-
imidazolium hexafluorophosphate (16a)
NMR (250 MHz, CDCl3) d 16.57 (s, 1H), 7.56–7.52 (m, 1H), 7.37–7.26
To a stirred solution of 15a (0.8 g, 2.37 mmol) in anhydrous
CH3CN (15 mL) was added NaPF6 (0.48 g, 2.85 mmol). The resulting
mixture was stirred for 12 h, and then filtered through Celite. After
evaporation of solvent, the residue was dissolved in methylene
chloride, and washed with water, and evaporated to give 16a as
dark yellow oil (0.95 g, 97.6%). The spectral data of major isomer: 1H
(m, 4H), 6.96–6.87 (m, 4H), 6.50–6.43 (m, 1H), 4.99–4.93 (m, 1H),
4.30–4.17 (m, 5H), 3.62–3.48 (m, 4H), 2.53–2.30 (m, 21H), 1.30 (d,
J¼6.3 Hz, 3H) ppm; 13C NMR (62.5 MHz, CDCl3)
d 296.6, 209.0,
151.4, 144.8, 144.3, 139.2, 130.0, 129.4, 128.9, 126.4, 123.6, 122.6,
122.0, 114.0, 111.2, 75.3, 51.7, 35.0, 21.0, 19.5, 17.4, 16.8, 9.6 ppm. IR:
3066, 2197, 2082, 1972, 1258, 843, 733, 552 cmꢂ1; HRMS (m/z)
Calcd for [MꢂHPF6]þ: C36H45Cl2N4ORuþ: 721.2018. Found:
721.2026.
NMR (250 MHz, acetone)
d
8.93 (s, 1H), 7.72 (d, J¼1.4 Hz, 1H), 7.62
(d, J¼1.3 Hz,1H), 7.44 (dd, J¼7.6,1.6 Hz,1H), 7.21–7.12 (m,1H), 6.99–
6.89 (m, 2H), 6.71 (dd, J¼15.9, 1.5 Hz, 1H), 6.23 (dq, J¼15.9, 6.6 Hz,
1H), 4.96–4.92 (m, 1H), 4.67–4.57 (m, 2H), 3.99 (s, 3H), 1.88 (dd,
J¼6.6, 1.5 Hz, 3H), 1.33 (d, J¼6.1 Hz, 3H) ppm; 13C NMR (62.5 MHz,
4.3. Olefin metathesis in ionic liquid
acetone)
d 154.2, 138.1, 131.3, 129.1, 128.9, 127.3, 126.2, 124.6, 124.2,
122.7, 115.3, 73.8, 54.8, 36.7, 19.0, 17.0 ppm. IR: 3165, 3058, 2990,
4.3.1. A typical procedure for ring-closing metathesis in ionic liquid
using imidazolium ion-tagged catalysts
1594, 1447, 1258, 1176, 852, 739, 553 cmꢂ1
.
A solution of 7b (3.68 mg, 4.0ꢁ10ꢂ3 mmol) in a mixture of
[bmim][PF6]/CH2Cl2 (1.0 mL/1.0 mL) (or [bdmim][PF6]/toluene,
0.5 mL/1.5 mL) was stirred at room temperature for 1 h, at which
point diene 17a (100 mg, 0.4 mmol) was added. The reaction mix-
ture was stirred until completion of the conversion (by TLC). After
evaporation of CH2Cl2, the ionic liquid layer was extracted with dry
diethyl ether (2 mLꢁ5), and then the diethyl ether was evaporated.
For the [bmim][PF6]/toluene solvent system: the toluene layer was
separated and then the ionic liquid layer was extracted with tolu-
ene (2 mLꢁ5). After evaporation of the diethyl ether (or toluene),
the crude residue was subjected to GC and 1H NMR analyses to
reveal complete conversion. The ionic liquid phase containing 7b
was reused for subsequent runs.
4.2.12. 2,3-Methyl-1-[2-(2-propenylphenoxy)]propyl-3H-
imidazolium hexafluorophosphate (16b)
Prepared by the same method for 16a using 15b. Yield: 98%. The
spectral data of major isomer: 1H NMR (250 MHz, acetone)
d 7.70
(d, J¼2.1 Hz, 1H), 7.60 (d, J¼2.1 Hz, 1H), 7.44 (dd, J¼7.7, 1.5 Hz, 1H),
7.15–7.12 (m, 1H), 6.97–6.88 (m, 2H), 6.65 (dq, J¼15.9, 1.5 Hz, 1H),
6.24 (dq, J¼15.9, 6.6 Hz, 1H), 4.99–4.97 (m, 1H), 4.70–4.64 (m, 2H),
3.94 (s, 3H), 2.85 (s, 3H), 1.87 (dd, J¼6.6, 1.5 Hz, 3H), 1.40 (d,
J¼6.1 Hz, 3H) ppm; 13C NMR (62.5 MHz, CD2Cl2)
d 153.1, 145.3,
128.9, 128.3, 127.6, 127.0, 125.5, 122.8, 122.5, 122.2, 114.5, 73.4, 35.6,
19.0, 17.0, 14.7, 10.2 ppm. IR: 3061, 2993, 2310, 1421, 1258, 846, 756,
710, 553 cmꢂ1
.